1 research outputs found
TARGET THERAPY FOR PATIENTS WITH NEUROFIBROMATOSIS (LITERATURE REVIEW)
ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΠΎΠ³ΠΎ ΠΎΠ±Π·ΠΎΡΠ° ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»Π΅Π½Π° Π²ΡΡΠΎΠΊΠΎΠΉ ΡΠ°ΡΡΠΎΡΠΎΠΉ Π½Π΅ΠΉΡΠΎΡΠΈΠ±ΡΠΎΠΌΠ°ΡΠΎΠ·Π° 1 ΡΠΈΠΏΠ° (NF1) ΠΈ Π½Π΅ΠΉΡΠΎΡΠΈΠ±ΡΠΎΠΌΠ°ΡΠΎΠ· 2 ΡΠΈΠΏΠ° (NF2) Π² ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ ΠΈ ΡΠ°ΡΡΠΎΠΉ Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΠ΅ΠΉ Ρ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ΠΌ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ. Π¦Π΅Π»ΡΡ ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠΈ ΠΎΠ±Π·ΠΎΡΠ° ΡΠ²Π»ΡΠ΅ΡΡΡ Π°Π½Π°Π»ΠΈΠ· Π΄Π°Π½Π½ΡΡ
Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΎΠΏΠΈΡΡΠ²Π°ΡΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΠ°ΡΠ³Π΅ΡΠ½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π»Π΅ΡΠ΅Π½ΠΈΡ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π½Π΅ΠΉΡΠΎΡΠΈΠ±ΡΠΎΠΌΠ°ΡΠΎΠ·ΠΎΠΌ Π Π΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌΠΈ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠΈΡΠΊΠ° ΡΡΠ°Π»ΠΎ ΠΎΠ±ΠΎΠ±ΡΠ΅Π½ΠΈΠ΅ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ΠΎΠ² ΠΊ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΡΠ°ΡΠ³Π΅ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π½Π΅ΠΉΡΠΎΡΠ±ΡΠΎΠΌΠ°ΡΠΎΠ·Π° ΠΊΠ°ΠΊ NF1, ΡΠ°ΠΊ ΠΈ NF2 ΡΠΈΠΏΠΎΠ². ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ Π΄Π°Π½Π½ΡΠ΅ ΠΎ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ³Π΅Π½Π΅ΡΠΈΠΊΠ΅ ΠΈ ΠΏΡΠΈΠ½ΡΠΈΠΏΠ°Ρ
ΡΡΠΈΠΎΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΠ»Π΅Π΄ΡΡΡΠΈΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΡΠ°ΡΠ³Π΅ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ: Π±Π΅Π²Π°ΡΠΈΠ·ΡΠΌΠ°Π±, ΡΡΠ»ΠΎΡΠΈΠ½ΠΈΠ±, ΠΈΠΌΠ°ΡΠΈΠ½ΠΈΠ±, ΡΠΎΡΠ°ΡΠ΅Π½ΠΈΠ±., ΡΠΈΡΠΎΠ»ΠΈΠΌΡΡ. Π‘Π²ΠΎΠ΄Π½Π°Ρ ΡΠ°Π±Π»ΠΈΡΠ° Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌΠΈ ΠΎΠ±Π·ΠΎΡΠ° ΡΠΎΠ΄Π΅ΡΠΆΠΈΡ ΡΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΈΠ· 39 Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ½ΡΡ
ΠΈΡΡΠΎΡΠ½ΠΈΠΊΠΎΠ². ΠΠΎ ΠΌΠ½Π΅Π½ΠΈΡ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π° Π°Π²ΡΠΎΡΠΎΠ², ΠΈΠ½Π½ΠΎΠ²Π°ΡΠΈΠΎΠ½Π½Π°Ρ ΡΠ°ΡΠ³Π΅ΡΠ½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π½Π΅ΠΉΡΠΎΡΠΈΠ±ΡΠΎΠΌΠ°ΡΠΎΠ·Π° ΠΌΠΎΠΆΠ΅Ρ ΠΎΠΊΠ°Π·Π°ΡΡΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ Ρ ΠΌΠ½ΠΎΠ³ΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½ΡΠ½Π½ΡΠΌΠΈ ΡΠΎΡΠΌΠ°ΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ.Β The relevance of the presented review is due to the high incidence of type 1 neurofibromatosis (NF1) and type 2 neurofibromatosis (NF2) in the population and frequent association with the development of malignant neoplasms. The purpose of the review is to analyze literature data that describe the results of the use of targeted drugs for the treatment of neoplasms in patients with neurofibromatosis. The results of the literary search became a generalization of modern approaches to targeted therapy of neurofromatosis both NF1 and NF2 types. The results of the literary search became a generalization of modern approaches to targeted therapy of neurofromatosis both NF1 and NF2 types. Data on pharmacogenetics and the principles of etiopathogenetic therapy with the use of the following targeted therapy are presented: bevacizumab, erlotinib, imatinib, sorafenib, sirolimus. The summary table with the results of the survey contains information from 39 literature sources. According to the majority of authors, innovative target therapy of neurofibromatosis can be effective in many patients with advanced forms of the disease